Grab 20% Off With Code ONLINE20 On Global market Reports – Evaluate Global Trends, Market Risks, and Competitive Intelligence
What Is the Forecasted Market Size of the Geographic Atrophy Market by 2029?
The geographic atrophy market size has grown rapidly in recent years. It will grow from $1.86 billion in 2024 to $2.11 billion in 2025 at a compound annual growth rate (CAGR) of 13.7%. The growth in the historic period can be attributed to growing geriatric population, rising demand for effective treatment options, increasing prevalence of geographic atrophy, increasing health awareness, and rise in incidence of retinal diseases.
The geographic atrophy market size is expected to see rapid growth in the next few years. It will grow to " $3.47 billion in 2029 at a compound annual growth rate (CAGR) of 13.2%. The growth in the forecast period can be attributed to rising focus on research and development, increase in R&D investments, escalating usage of smartphones, increasing expenditure on healthcare, and increased investment in clinical trials. Major trends in the forecast period include advancements in gene therapy, advances in healthcare technology, development of new technologies, telemedicine adoption, and innovative and effective drugs.
Get your free report sample today:
What Are the Major Drivers Propelling the Growth of the Geographic Atrophy Market?
Increasing prevalence of age-related macular degeneration is expected to propel the growth of the geographic atrophy market going forward. Age-related macular degeneration (AMD) is an eye condition that damages the central part of the retina of the older adults, making it difficult to see fine details. Aging population is the major reason for the prevalence of age-related macular degeneration, as more people are living longer, and the natural aging process causes gradual damage to the eyes, making them more vulnerable to the disease over time. Geographic atrophy treatment support age-related macular degeneration (AMD) patients by slowing the progression of retinal damage and preserving remaining vision. For instance, in January 2024, according to a report published by Medical News Today, a US-based digital media company, the global cases of age-related macular degeneration are expected to rise from 196 million to 288 million by 2040. Therefore, the increasing prevalence of age-related macular degeneration is driving the growth of the geographic atrophy market.
How Is the Geographic Atrophy Market Structured Across Its Key Segment Categories?
The geographic atrophymarket covered in this report is segmented –
1) By Drug Type: Anti-Vascular Endothelial Growth Factor (VEGF) Therapy; Complement Inhibitors; Neuroprotective Agents; Other Drugs
2) By Diagnosis: Fundus Autofluorescence (FAF); Optical Coherence Tomography Angiography (OCT-A); Multifocal Electroretinography (mfERG)
3) By Route Of Administration: Intravitreal; Oral; Other Routes Of Administration
4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies; Other Distribution Channels
Subsegments:
1) By Anti-Vascular Endothelial Growth Factor (VEGF) Therapy: Ranibizumab; Aflibercept; Bevacizumab
2) By Complement Inhibitors: Pegcetacoplan; Lfg316
3) By Neuroprotective Agents: Latanoprost; Brimonidine
4) By Other Drugs: Steroids; Retinoids; Combination Therapy
Which Disruptive Trends Are Reshaping the Competitive Landscape of the Geographic Atrophy Market?
Major companies operating in the geographic atrophy market are focusing on innovative therapies such as complement inhibitor therapy to develop advanced treatments for geographic atrophy. Complement inhibitor therapy is a treatment that slows down an overactive immune response linked to certain diseases and helps protect healthy cells from damage and reduces disease progression. For instance, in February 2025, Astellas Pharma Inc., a Japan-based pharmaceutical company announced IZERVAY (avacincaptad pegol intravitreal solution) for geographic atrophy approved by the Food and Drug Administration, a US-based government agency. This approval allows IZERVAY to be used without a limitation on the duration of dosing for treating geographic atrophy (GA) secondary to age-related macular degeneration (AMD). This decision provides greater flexibility for managing GA, offering longer-term treatment options for both patients and healthcare providers.
Which Companies Are Recognized as Major Innovators in the Geographic Atrophy Market?
Major companies operating in the geographic atrophy market are Regeneron Pharmaceuticals Inc., Boehringer Ingelheim, Astellas Pharma Inc., Biogen Inc., Ocugen Inc., Kodiak Sciences Inc., Apellis Pharmaceuticals Inc., NGM Biopharmaceuticals Inc., Voyager Therapeutics, Kriya Therapeutics, Stealth BioTherapeutics, Kiora Pharmaceuticals, Iveric Bio, Alkeus Pharmaceuticals, Nanoscope Therapeutics, Graybug Vision, SparingVision, 4D Molecular Therapeutics, Clearside Biomedical, Gensight Biologics
Get the detailed geographic atrophy market report today
Which Regional Markets Are Likely to See the Most Significant Expansion in the Coming Years?
North America was the largest region in the geographic atrophy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the geographic atrophy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Contact Us:
The Business Research Company: https://thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: info@tbrc.info
Follow Us On:
LinkedIn: The Business Research Company | LinkedIn
Comments
Post a Comment